Health Condition 1: F902- Attention-deficit hyperactivity disorder, combined type
Conditions
Interventions
Control Intervention1: NIL: NIL
Sponsors
Amrita Institute of Medical Sciences and Research Centre
Eligibility
Inclusion criteria
Inclusion criteria: 1A. Healthy children (Controls): Children with no current medical illness and family history of any major psychiatric disorder, especially ADHD as defined by ICD-10/ DSM-V. 1B. ADHD patients (Cases): Children diagnosed with ADHD by the paediatrician and the clinical psychologist using the Vanderbilt ADHD rating scale and who are on therapy or not. Comorbid with ODD, SLD, and CD will be included. 2. Willing to withdraw blood and participate in the study after giving consent. 3. Responsible caregiver to provide sufficient information about the participant’s functional status.
Exclusion criteria
Exclusion criteria: 1. History of any neurological disorder and psychiatric conditions involving the brain or other central function (eg: History of brain injury, suspected intellectual disability, autism spectrum disorder, narcolepsy, H/O mental retardation (MR), schizophrenia, mania episode, epilepsy, anxiety disorders, bipolar disorder, active suicidal ideation) 2. Use of Anticoagulants 3. Having any serious medical condition, including inflammatory bowel disease, history of cancer, kidney or liver disease, hyperthyroidism, glaucoma, diabetes or cardiovascular disorders, gallstones, bile duct obstruction, stomach ulcers, or excess stomach acid, abnormality of mineral metabolism eg: Wilson’s disease, hemochromatosis 4. Having any disability that would interfere with participation in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Evaluation of serum Vitamin D levels will help to rule out the deficiency VDR gene polymorphism analysis will help to identify the alteration in the VDR gene that might affect the bioconversion of vitamin D in ADHDTimepoint: At the baseline visit alone, the blood samples will be collected. The serum will be separated for vitamin D estimation and DNA will be isolated for polymorphism analysis. | — |
Secondary
| Measure | Time frame |
|---|---|
| The expression analysis of dopamine-specific genes (TH,DRD4,SLC6A3) & VDR will help to elucidate molecular-level changes that will affect the pathophysiology of ADHD. The genomic analysis of these ADHD-specific genes can be used as an efficient biomarker for ADHD. It will help to improve the treatment outcome by individualizing the treatment modalities accordingly Timepoint: At the baseline visit alone, Blood samples will be collected & mRNA will be isolated | — |
Countries
India
Contacts
Public ContactMintu Mathew
Amrita School of Pharmacy
Outcome results
None listed